Circulating cell‐free epstein–barr virus DNA levels and clinical features in Moroccan patients with nasopharyngeal carcinoma

Gihbid, Amina; Benzeid, Raja; Faouzi, Abdellah; Nourlil, Jalal; Tawfiq, N.; Benchakroun, Nadia; Guensi, A.; Bendahhou, Karima; Benider, Abdellatif; Benna, Naima El; Chaoui, Imane; Cadi, Rachida; Mzibri, Mohammed El; Khyatti, Meriem

doi:10.1186/s13027-021-00353-8

Cited by 15 publications

(17 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 It is widely recognized that the TNM stage system and the Epstein-Barr virus (EBV) DNA play important roles in guiding NPC treatment, evaluation of curative efficacy, as well as prognosis prediction. 6 However, clinical outcomes significantly vary even among NPC patients with the same TNM stage and similar therapeutic regimens. 7 Moreover, EBV-DNA testing is a complex detection process, and is further characterized by the high cost of testing, and huge discrepancies in results, which consequently limit its promotion and practical application.…”

Section: Introductionmentioning

confidence: 99%

Prognostic Value of Inflammatory Markers in Nasopharyngeal Carcinoma Patients in the Intensity-Modulated Radiotherapy Era

Yang

et al. 2021

CMAR

View full text Add to dashboard Cite

Purpose: Inflammatory markers have been widely used in various cancers, but rarely in nasopharyngeal carcinoma (NPC). Here, we evaluated the prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR), platelet-lymphocyte-ratio (PLR), systemic immune index (SII), and systemic inflammation response index (SIRI) on NPC in the intensitymodulated radiotherapy (IMRT) era. Methods: We retrospectively analyzed data from NPC patients from the Renmin Hospital of Wuhan University, between January 2012 and July 2020. We used Chi-square test or Fisher's exact test to compare the baseline characteristics, then applied Kaplan-Meier (K-M) survival analysis to compare the overall survival (OS) and progression-free survival (PFS) rates. Multivariate Cox proportional risk models were applied to identify independent prognostic factors. Results: We enrolled a total of 342 NPC patients and found optimal cut-off values of 2.65, 184.91, 804.08, and 1.34 for NLR, PLR, SII, and SIRI, respectively. K-M survival analysis revealed that high NLR, PLR, SII, and SIRI were significantly associated with worse OS and PFS relative to those in the low groups. Results from univariate Cox analysis showed that clinical, T, and M stages, as well as NLR, PLR, SII, and SIRI were associated with OS, whereas age, alongside the aforementioned parameters, was associated with PFS. Moreover, multivariate Cox analysis showed that age ≥49 years (HR=2.48, 95% CI=1.21-5.05, P=0.013) and M1 stage (HR=3.84, 95% CI=1.52-9.73, P=0.013) were independent prognostic factors for OS, whereas SIRI ≥1.34 (HR=1.91, 95% CI=1.05-3.47, P=0.034) and M1 stage (HR=2.91, 95% CI=1.44-5.86, P=0.003) were independent prognostic factors for PFS. Conclusion: Overall, our findings indicated that high NLR, PLR, SII, and SIRI were significantly associated with poor OS and PFS in NPC patients. High SIRI may be an independent risk factor for PFS of NPC patients in the IMRT era.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic Value of Inflammatory Markers in Nasopharyngeal Carcinoma Patients in the Intensity-Modulated Radiotherapy Era

Yang

et al. 2021

CMAR

View full text Add to dashboard Cite

show abstract

“…In the previous decade, many studies have shown that EBV DNA viral load is a sensitive and non-invasive biomarker for monitoring NPC. In the study by Gihbid et al, plasma EBV DNA levels were 4 times higher in patients over 30 years old [15], [16], [17], [18], [19], [20].…”

Section: Discussionmentioning

confidence: 99%

Platelet to Lymphocytes Ratio to Predict Nasopharyngeal Carcinoma Progressivity

Yudistira

Dewi

Sudiro

2022

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Nasopharyngeal carcinoma (NPC) is a head and neck cancer that arises from the nasopharyngeal epithelium. It is one of the most common malignancies in Southeast Asia. In 2020, there were 133,354 new cases of NPC worldwide, with 113,659 occurring on the Asian continent (85.2%). In Indonesia, the prevalence of NPC is 6.2/100,000 people, with 13,000 new cases each year. NPC was the most frequent head and neck cancer in the Otorhinolaryngology-Head and Neck Surgery Department Dr. Hasan Sadikin Hospital Bandung from 2013 to 2018, with 921 (35.20%) new cases. AIM: Platelet-to-lymphocyte-ratio (PLR) testing has the potential to be employed as a prognostic marker in the evaluation of NPC. The purpose of this study is to investigate the link between PLR and the clinical stage of NPC. METHODS: Between 2016 and 2020, a cross-sectional study was conducted on NPC patients at Hasan Sadikin Hospital in Bandung. Patient information was gathered from the registry of the Oncology Head and Neck Surgery Study Group. Three hundred and eighty-three people met the requirements for inclusion. RESULTS: Lymph node metastases (p = 0.001), distant metastases (p = 0.001), and clinical stage (p < 0.001) are all classified differently by PLR. The platelet to lymphocytes ratio was linked to lymph node metastasis, distant metastases, and clinical stage in a statistically significant (p < 0.05). Patients with a PLR >287 have a 3.69 times chance of developing distant metastases, while those with a PLR >160 have a 1.38 times chance of progressing to the advanced stage. CONCLUSION: PLR is linked to the nasopharyngeal cancer clinical stage. Furthermore, in NPC patients, PLR can predict advanced stage and distant metastases.

show abstract

“…The correlation between pre-treatment EBV DNA load and conventional prognostic factors showed a significant association with patients’ age, tumour classification, lymph node status, metastatic status and overall cancer stage ( p = 0.01). The results of this study clearly demonstrated a high association between pre-treatment EBV DNA load, important classical prognostic factors (T, N, M and disease stage) of NPC and suggested that pre-treatment EBV DNA load can be a useful prognostic biomarker and improve the treatment of NPC [ 36 ].…”

Section: Discussionmentioning

confidence: 99%

“…Gihbid et al[36] evaluated the correlation between pre-treatment plasma EBV DNA load and conventional prognostic factors in Moroccan NPC patients. Measuring the pre-treatment EBV plasma load, 90.9% of the patients had detectable EBV DNA, with a mean plasma viral load of 7,710 IU/mL.…”

mentioning

confidence: 99%

Epstein–Barr virus nuclear antigen-1 is useful as therapeutic efficacy marker in serum but not in saliva of nasopharyngeal cancer patients who underwent radiotherapy

Midoen¹,

Suryandari²,

Yunaini³

et al. 2021

ecancer

View full text Add to dashboard Cite

Introduction: Nasopharyngeal carcinoma (NPC) is a multifactorial disease with genetic, viral, environmental and lifestyle-related risk factors. Epstein-Barr virus (EBV) can promote the oncogenic transformation of an infected cell into malignant. EBV encodes many stimulating products including Epstein-Barr virus nuclear antigen-1 (EBNA-1) which plays a key role in the regulation of gene expression and replication of the genome in the latent period of infection. EBNA-1 in serum and tumour tissue of NPC patients correlates with NPC prognosis. Moreover, the presence of EBV DNA in serum samples from NPC patients' blood circulation can be used as an early marker in the diagnosis of NPC. Objective:The objective of this study was to find effective methods for monitoring the progress of NPC patients undergoing radiotherapy and therapeutic efficacy by observing the changes in EBV DNA in serum and saliva. Methodology:The pre-experimental design compared blood and saliva taken from a pretest and post-test group of NPC patients before and after radiation therapy. The concentration of EBV DNA was measured in the serum and saliva after amplification using quantitative polymerase chain reaction (qPCR) with compatible primers for the EBNA-1 gene. The data were statistically analysed by paired T-test.Results: Highly significant (p = 0.0001) increase in cycle threshold qPCR and decrease in the mean concentration of EBV DNA (p = 0.0001) were observed in serum samples, but no significant changes were observed in saliva. Conclusions:The results suggest that EBV DNA in serum can be used as the gold standard and a marker for monitoring the response to radiation therapy in NPC patients, whereas the examination of EBV DNA from saliva samples is not accurate and thus, not appropriate.

show abstract

Circulating cell‐free epstein–barr virus DNA levels and clinical features in Moroccan patients with nasopharyngeal carcinoma

Cited by 15 publications

References 23 publications

Prognostic Value of Inflammatory Markers in Nasopharyngeal Carcinoma Patients in the Intensity-Modulated Radiotherapy Era

Prognostic Value of Inflammatory Markers in Nasopharyngeal Carcinoma Patients in the Intensity-Modulated Radiotherapy Era

Platelet to Lymphocytes Ratio to Predict Nasopharyngeal Carcinoma Progressivity

Epstein–Barr virus nuclear antigen-1 is useful as therapeutic efficacy marker in serum but not in saliva of nasopharyngeal cancer patients who underwent radiotherapy

Contact Info

Product

Resources

About